Curriculum Vitaes
Profile Information
- Affiliation
- School of Medicine, Fujita Health University
- Degree
- 医学博士(東北大学)
- Researcher number
- 00455833
- J-GLOBAL ID
- 201801021106693329
- researchmap Member ID
- B000314749
Research Interests
5Research Areas
4Research History
9-
Jan, 2012 - Jun, 2013
-
Jul, 2009 - Dec, 2012
-
Jul, 2007 - Jun, 2009
Education
2-
Apr, 2001 - Mar, 2005
-
Apr, 1992 - Mar, 1998
Committee Memberships
1-
Apr, 2019 - Present
Awards
5Papers
109-
Transplantation proceedings, 56(5) 1179-1182, Jun, 2024A 41-year-old woman with lymphangioleiomyomatosis developed a bronchial anastomotic stenosis after left single lung transplantation (LTx). A part of the hyperinflated right native lung was excised in an attempt to remedy the left lung compression, which appeared to affect the bronchial anastomotic stenosis and ventilation/perfusion mismatch. However, a persistent air leak after the surgery caused empyema and an open window thoracotomy (OWT) was performed. She remained oxygen-dependent and was relisted for lung transplantation. A right single LTx on the side of OWT was performed, achieving long-term survival with no activity limitations for the patient. We report here the first successful LTx after OWT for empyema.
-
Journal of thoracic disease, 16(2) 1473-1479, Feb 29, 2024BACKGROUND: Despite the low number of lung transplantations (LTs) in Japan, 10 LT facilities are accredited and good outcomes have been reported. A database review was conducted to clarify the impact of case volume at LT facilities in Japan on short- and long-term outcomes. METHODS: All cadaveric LT cases treated between 2000 and 2021 in Japan were analyzed using the database of the Japanese Society of Lung and Heart-Lung Transplantation (JSLHT). The nine institutions represented were categorized into the low-volume (LV; <80 cumulative LT cases, <8 LTs/year, n=5) and high-volume (HV; ≥80 cumulative LT cases, ≥8 LTs/year, n=4) centers. Ninety-day and 1-year mortality, as well as 5- and 10-year survival data were evaluated. RESULTS: A total of 658 cadaveric LTs were performed at the nine institutions. The 90-day rates of mortality at the HV and LV centers were 3.5% and 3.9%, respectively (P=0.801), while the 1-year mortality rates were 9.2% and 11.5%, respectively (P=0.199). Additionally, log-rank analysis of Kaplan-Meier curves showing case volume did not reveal a significant difference in long-term survival between the HV and LV centers (P=0.272), though the LV centers had wide differences for long-term outcomes (P=0.030). CONCLUSIONS: Case volume did not have effects on short- or long-term outcomes following LT in Japan, while there were large variations in long-term outcomes among the LV centers compared to those of the HV centers.
-
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 63(6), Jun 1, 2023OBJECTIVES: Standard bilateral lung transplantation (BLT) is not feasible for patients with pulmonary arterial hypertension (PAH) complicated with a giant pulmonary arterial aneurysm (PAA). This study aimed to describe the outcomes of BLT with pulmonary artery reconstruction (PAR) using donor aorta for such patients. METHODS: This is a retrospective single-centre study reviewing PAH patients with a PAA who received BLT with PAR using donor aorta from January 2010 through December 2020. We compared the characteristics and short- and long-term outcomes of recipients receiving PAR (PAR group) with those who had no PAA and received standard BLT (non-PAR group). RESULTS: Nineteen adult PAH patients underwent cadaveric lung transplantation during the study period. Among them, 5 patients with a giant PAA (median pulmonary artery trunk diameter, 69.9 mm) underwent BLT with PAR using donor aorta and the others received standard BLT. Although the operation time tended to be longer in the PAR group compared with the non-PAR group (1239 vs 958 mins, P = 0.087), 90-day mortality (PAR group: 0% vs non-PAR group: 14.3%, P > 0.99), and 5-year survival rate (PAR group: 100% vs non-PAR group: 85.7%, P = 0.74) was comparable between the groups. No dilatation, constriction or infection of the aortic grafts were recorded during the study period with a median follow-up time of 94 months in the PAR group. CONCLUSIONS: Lung transplantation with PAR using donor aorta is a valid surgical option for PAH patients complicated with a giant PAA.
-
Surgery today, Apr 19, 2023PURPOSE: To clarify the impact of donor and recipient characteristics on the survival of recipients before and after lung transplantation in the Japanese population. METHODS: Patients' data were collected for retrospective analysis from all authorized lung transplant centers in Japan. We included 1963 patients listed for lung transplantation by the end of December 2021, comprised of 658 deceased-donor and 270 living-donor lung transplants. RESULTS: Primary disease had a significant impact on the mortality of patients waiting for transplantation. The indications for transplant significantly affected the post-transplant survival rate of deceased-donor lung transplant recipients. The recipient's age also significantly affected the post-transplant survival rate of the deceased-donor and living-donor lung transplant recipients. The recipients of grafts transplanted from donors aged 61 years or older showed a worse post-transplant survival rate (≧60 years old). The survival rate for the combination of a female donor to a male recipient among the deceased-donor lung transplant recipients was the worst among the four combinations. CONCLUSION: The donor and recipient characteristics significantly impacted the survival of recipients after lung transplantation. The underlying mechanism of the negative impact of the gender mismatch of female donor to male recipient on post-transplant survival needs to be investigated further.
Misc.
374-
移植, 51(2-3) 81-83, Aug, 2016<p>Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells) that lead to cystic destruction of the lungs, chylous effusions, and the formation of lymphangioleiomyomas. Although lung transplantation for LAM accounts for only 1% of all lung transplant procedures in the International Registry, it does account for 16% in the Japanese Registry, and LAM is one of the major indications in Japanese lung transplantation. Recurrence of LAM in the allograft is one of the disease-specific complications after lung transplantation. The rates of recurrence, however, have been reported to be <10%, and the recurrence rarely affects the recipient's prognosis. Recently, sirolimus, an mTOR inhibitor, emerged as a therapeutic drug for LAM and is also expected to be effective for the recurrence of LAM after lung transplantation.</p>
-
移植, 51(2-3) 244-244, Aug, 2016
-
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 35(4) S177-S178, Apr, 2016
-
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 35(4) S234-S234, Apr, 2016
-
内科, 117(3) 471-474, Mar, 2016
-
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193, 2016
-
Organ Biology, 23(2) 141-144, 2016Mycophenolate mofetil (MMF) has been used as a standard immunosuppressive agent after lung transplantation. MMF is rapidly metabolized to active constituent, mycophenolic acid (MPA), after intake. Gastrointestinal side- effects and leukocytopenia are common adverse effects of MMF. Although, therapeutic drug monitoring (TDM) for calcineurin inhibitors is widely used, the role of TDM for MPA is unclear in lung transplantation. We investigated the correlation among the blood concentration of MPA, the dosage of MMF and the number of leukocyte in lung transplant recipients. The correlation coefficient between the blood concentration of MPA and the dosage of MMF was not significant, so MMF might require TDM. On the other hand, neither the correlation coefficients between the number of leukocyte and the blood concentration of MPA nor the correlation coefficients between the number of leukocyte and the dosage of MMF were not significant. Further investigation is necessary to find the meanings of TDM for MPA after lung transplantation.
-
Japanese Journal of Transplantation, 51(2) 81-83, 2016<p>Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells) that lead to cystic destruction of the lungs, chylous effusions, and the formation of lymphangioleiomyomas. Although lung transplantation for LAM accounts for only 1% of all lung transplant procedures in the International Registry, it does account for 16% in the Japanese Registry, and LAM is one of the major indications in Japanese lung transplantation. Recurrence of LAM in the allograft is one of the disease-specific complications after lung transplantation. The rates of recurrence, however, have been reported to be <10%, and the recurrence rarely affects the recipient's prognosis. Recently, sirolimus, an mTOR inhibitor, emerged as a therapeutic drug for LAM and is also expected to be effective for the recurrence of LAM after lung transplantation.</p>
-
胸部外科, 69(1) 25-29, Jan, 2016高齢者肺切除例における術前の歯科への口腔ケア介入依頼状況と術後肺炎発症率について検討した。肺切除術を施行した65歳以上の159例(男性103名、女性56名、65〜84歳)を対象とした。術前の歯科医師による口腔ケア介入は61例で施行された。術後肺炎は4例で発症し、1例が死亡した。術前歯科医師への口腔ケア介入依頼率は、2013年30.3%、2014年45.8%と2014年で増加傾向を認めた。術後肺炎は2013年3例、2014年は1例で発症した。2013年の術後肺炎発症例3例中1例が在院死した。2014年には在院死はなかった。2013年の3例中2例はいずれも術前歯科非介入例であった。
-
TRANSPLANT INTERNATIONAL, 28 306-306, Nov, 2015
-
TRANSPLANT INTERNATIONAL, 28 521-521, Nov, 2015
-
TRANSPLANT INTERNATIONAL, 28 376-376, Nov, 2015
-
日本医療薬学会年会講演要旨集, 25 328-328, Oct 23, 2015
Books and Other Publications
3Teaching Experience
2-
Apr, 2020 - Presentpneumothorax, metastatic lung tumor, empyema (Fujita Health University)
-
mediastinal tumors (Tohoku University)
Professional Memberships
12Research Projects
13-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Oct, 2020 - Mar, 2024
-
科学研究費助成事業 基盤研究(C), 日本学術振興会, Apr, 2019 - Mar, 2024
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2023
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2018 - Mar, 2022
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2018 - Mar, 2021